Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration

Author(s):  Trissel Lawrence A, Saenz Christopher, Williams Kimberly Y, Ingram Delshalonda S

Issue:  Jul/Aug 2001 - Sterile Product Compounding
View All Articles in Issue

Page(s):  314-319

Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Page 1
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Page 2
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Page 3
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Page 4
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Page 5
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Page 6

Download in electronic PDF format for $75

Abstract:  The physical compatibility of lansoprazole injection with selected other drugs during simulated Y-site coadministration was evaluated by means of visual observation, turbidity measurement, and particle content assessment.

Five-milliliter samples of lansoprazole 0.55 mg/mL in 0.9% sodium chloride injection were combined with 5 mL of 112 other drugs including antineoplastics, analgesics, antiinfectives, and supportive-care drugs undiluted or diluted in 0.9% sodium chloride injection or 5% dextrose injection for amphotericin B. Visual examinations were performed with the unaided eye in fluorescent light and by means of a Tyndall beam (a high-intensity, monodirectional light beam) to enhance the visualization of small particles and low-level turbidity. The turbidity of each sample was measured as well. Particle sizing and counting were performed on selected samples. Evaluation of the samples was performed initially and at 1 and 4 hours after preparation.

Of the drugs tested, 92 were incompatible with lansoprazole 0.55 mg/mL in 0.9% sodium chloride injection during the 4-hour observation period. Gross precipitation or color changes visible in normal diffuse room light with the unaided eye occurred with 45 drugs. Phenomena not visible with the unaided eye, such as microprecipitation and/or increases in measured turbidity, occurred with 47 drugs. Only 20 drugs were found to be compatible for at least 4 hours. The measured turbidity of the lansoprazole control solutions and the compatible test samples remained essentially unchanged throughout the study. In addition, the compatible samples exhibited no color change or substantial change in particle size and content throughout the observation period.

In combination with lansoprazole, only 20 drugs were considered to be physically compatible. Ninety-two drugs exhibited frank precipitation, microparticulate formation, color changes, or unacceptable increases of measured turbidity within 4 hours and should not be simultaneously coadministered with lansoprazole.

Related Keywords: Lansoprazole injection, incompatibilities, Y-site coadministration

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration
Trissel Lawrence A
, Saenz Christopher, Williams Kimberly Y, Ingram Delshalonda S
Jul/Aug 2001
Pg. 314-319

Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration
Chan Pak
, Heatherly Kathy, Kupiec Thomas C, Trissel Lawrence A
May/Jun 2008
Pg. 276-278

Compatibility Screening of Bivalirudin During Simulated Y-Site Administration with Other Drugs
Trissel Lawrence A
, Saenz Christopher
Jul/Aug 2002
Pg. 311-315

Compatibility Screening of Hextend During Simulated Y-Site Administration with Other Drugs
Trissel Lawrence A
, Williams Kimberly Y, Baker Ma
Jan/Feb 2001
Pg. 69-73

Compatibility of Micafungin Injection with Other Drugs During Simulated Y-Site Co-administration
Trusley Craig
, Kupiec Thomas C, Trissel Lawrence A
May/Jun 2006
Pg. 230-233

Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig
, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
Mar/Apr 2008
Pg. 156-160

Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C
, Ben Michel, Trusley Craig, Trissel Lawrence A
Mar/Apr 2008
Pg. 170-173

Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration
Lu Juan
, Liu Qiang, Kupiec Thomas C, Vail Herbert, Lynch Leslie R, Fam David S, Vu Nicole T
Jan/Feb 2021
Pg. 52-61

Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration
Trissel Lawrence A
, Gilbert Doward L, Wolkin Allan C
May/Jun 1999
Pg. 241-244

Compatibility Screening of Precedex During Simulated Y-Site Administration with Other Drugs
Trissel Lawrence A
, Saenz Christopher, Williams Kimberly Y, Ingram Delshalonda S, Retzinger Julie P
May/Jun 2002
Pg. 230-233

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Jul/Aug 2008
Pg. 368-371

Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration
Trissel Lawrence A
, Trusley Craig, Kupiec Thomas C, Ben Michel
Jan/Feb 2009
Pg. 78-80

Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration
Zhang Yang
, Scarlett Cameron, Hutson Paul
Jan/Feb 2012
Pg. 82-85

Compatibility of Amiodarone Hydrochloride with Vasopressin During Simulated Y-site Administration
Ramaley Corrine C
, Li Feng, Du Chengan
Sep/Oct 2013
Pg. 436-438

Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration
Trusley Craig
, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
Jan/Feb 2007
Pg. 82-85

Compatibility and Stability of Ranitidine Hydrochloride with Six Cephalosporins During Simulated Y-Site Administration
Inagaki Kazuhiro
, Kambara Motoya, Mizuno Munemichi, Gill Mark A, Nishida Mikio
Jul/Aug 1998
Pg. 318-321

Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration
Mody Vicky
, Shah Samit, Patel Jaymin, Thomas Michael C
May/Jun 2016
Pg. 236-238

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
Jan/Feb 2020
Pg. 44-50

Return to Top